news

we have heard many stories about corporate development and transformation. hengrui medicine, as a representative of traditional chinese pharmaceutical companies, started with generic drugs and gradually developed into me-too and me-better. it is now one of the local pharmaceutical companies with the richest pipelines. the 2024 half-year annual report shows that its operating income and net profit showed a large year-on-year positive growth. with the help of capital, beigene quickly built a pipeline and currently has independent hematopoietic capabilities. today, we are going to talk about yitong pharmaceutical, which has taken another successful practice of transformation from cso. in the past 10 years, through licensing, asset acquisition, technology transfer and other methods, yitong has achieved the listing of innovative drugs and the continuous growth of classic drugs, contributing a successful example of "reverse" transformation to the industry.

eddingpharm was founded in 2001. in the early days, it represented the products of various multinational pharmaceutical companies and was very successful. it once ranked among the top csos in china. due to its outstanding sales ability, eddingpharm has attracted the attention of many well-known investment institutions, such as orbimed, sequoia, and guangyuan, and became its investors.

afterwards, eddingpharm took the initiative to seek reforms. in 2019, through two asset acquisitions, it not only acquired the rights to three mature products, but also obtained the advanced production and manufacturing technology, global supply chain management capabilities and key processes of complex preparations of multinational pharmaceutical companies. this is an important strategic layout in eddingpharm's transformation, and is generally regarded by the industry as a typical case of chinese pharmaceutical companies introducing international pharmaceutical resources, expanding product pipelines and enhancing their core competitiveness in recent years.

in 2023, eddingpharm finally achieved the last breakthrough in its transformation. the launch of two innovative drugs by eddingpharm marked the vindication of its long-questioned r&d capabilities; the successful commercialization of new drugs will also help eddingpharm reach sales peaks one after another.

for eddington pharmaceuticals, sales capabilities are beyond doubt. it is precisely this long-term accumulated market experience that enables eddington to fully understand the real pain points of chinese clinical practice, so that it can clearly identify the therapeutic areas to be deeply cultivated during the transformation, and based on the insight into the forefront of drug development trends, select products that are suitable for the chinese market and have huge market prospects. looking at eddington's product line, whether it is the three classic products that have been on the market for many years or the two innovative drugs that have been launched recently, they have strong market competitiveness. in particular, the innovative cardiovascular drug visper, which was launched by eddington, was recently approved for its second indication in china to reduce the risk of cardiovascular events, which is expected to make eddington pharmaceuticals' sales achieve a qualitative leap in the next 3-5 years.

in addition to its excellent product judgment and expansion capabilities, eddingpharm has taken over the high-starting point of production and manufacturing and global supply chain capabilities from multinational pharmaceutical companies, which have also achieved sustained high-speed operation in recent years. its production company, eddingpharm (suzhou) co., ltd., was rated as a high-tech enterprise in 2023. it is reported that eddingpharm is currently actively promoting the localization of a number of original research drugs, strengthening cooperation with domestic and foreign research and development institutions, and striving to bring more and higher-quality products to chinese patients at a lower price. it is believed that as eddingpharm launches more and more innovative drugs, relying on its stable production and operation capabilities and strong back-end commercialization capabilities, this former king of china's cso will be reborn with a new attitude.

in the cold winter of the pharmaceutical industry, the companies that can finally come out and be proven by practice are often those that meet the clinical needs of chinese patients, make profits, and further feed back their own development through product revenue, thus achieving a virtuous cycle. i believe that such yitong will definitely gain recognition from the industry with its strength, and yitong will also have new opportunities on its road to listing.

source: enshi news network

(source: financial information)

for more exciting information, please download the "jimu news" client from the application market. please do not reprint without authorization. you are welcome to provide news clues, and you will be paid once adopted.